We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Rapid Test Detects Drugs of Abuse in Fingerprint Samples

By LabMedica International staff writers
Posted on 22 Oct 2018
Print article
Image: A rapid lateral flow drug test can detect four classes of drugs in traces of sweat found in fingerprints from both living and deceased individuals (Photo courtesy of Intelligent Fingerprinting).
Image: A rapid lateral flow drug test can detect four classes of drugs in traces of sweat found in fingerprints from both living and deceased individuals (Photo courtesy of Intelligent Fingerprinting).
A rapid lateral flow assay accurately detects drugs of abuse in finger print samples from living or deceased individuals.

Investigators at the University of East Anglia (Norwich, UK) and the biotechnology company Intelligent Fingerprinting (Cambridge, United Kingdom) developed a fluorescence based lateral flow competition assay for the screening of four classes of drugs: delta9-tetrahydrocannabinol (THC), cocaine (through the detection of benzoylecgonine, BZE), opiates (through the detection of morphine, MOR) and amphetamine (AMP) present in the sweat of a fingerprint. This "Drug Screening Cartridge" was specifically developed for fingerprint sample collection and analysis.

In addition to testing samples from living individuals, the investigators worked with three coroners in the United Kingdom to test the ability of the Drug Screening Cartridge, together with its fluorescence reader, to detect drugs in the sweat of a fingerprint from deceased individuals. The presence of the drugs was confirmed using LC–MS-MS analysis of a second fingerprint sample collected simultaneously.

This fingerprint sample method had a collection time of just five seconds and a total analysis time of less than 10 minutes. Results revealed that there was sufficient sweat present on the fingertips to enable analysis and that the Drug Screening Cartridge could detect the presence, or absence, of each drug. Excellent correlation was achieved between the results obtained from the Drug Screening Cartridge and the LC–MS-MS analysis of the fingerprint samples obtained from 75 individuals. The accuracy of the results was: 99% for THC, 95% for BZE, 96% for MOR, and 93% for AMP. The results obtained using the Drug Screening Cartridge were also compared to toxicological analysis of blood and urine samples with good correlation. The accuracy of the results between the Drug Screening Cartridge and blood was: 96%, 92%, 88%, and 97% for THC, BZE, MOR, and AMP, respectively. The comparison with urine showed an accuracy ranging between 86% and 92%.

Senior author Dr. David Russell, emeritus professor of chemistry at the University of East Anglia, said, "Our study also showed how our technology is being used by coroners to assist in gaining early understanding of the possible cause of death, and to inform potential further post-mortem activities or quickly facilitate police investigations. We matched the coroners' drug test results obtained using our fingerprint drug screen with a second sample tested in laboratory conditions, achieving excellent correlation in terms of accuracy. We also compared our results with toxicological analysis of blood and urine samples, with a good correlation of results."

The study was published in the October 1, 2018, online edition of the Journal of Analytical Toxicology.

Related Links:
University of East Anglia
Intelligent Fingerprinting

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Creatine Kinase-MB Assay
CK-MB Test
New
Cytomegalovirus Test
NovaLisa Cytomegalovirus (CMV) IgG Test

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.